Ezra M. Friedberg - 02 Jul 2025 Form 4 Insider Report for Pelthos Therapeutics Inc. (CHRO)

Reporting relationship: Director
Issuer ticker: CHRO
Reported as of: 02 Jul 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 07 Jul 2025, 21:42:40 UTC
Prior SEC filing: 03 Jul 2025
Next SEC filing: 26 Nov 2025
Source filing: View source filing
Reporting owner signature: /s/ Ezra Friedberg

Key filing fact

Ezra M. Friedberg filed Form 4 for Pelthos Therapeutics Inc. (CHRO) on 07 Jul 2025.

Key facts

This page summarizes Ezra M. Friedberg's Form 4 filing for Pelthos Therapeutics Inc. (CHRO).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 07 Jul 2025, 21:42.

Change

Previous filing in this sequence was filed on 03 Jul 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001679440 Primary reporting owner

Friedberg Ezra M

Relationship: Director
Address: C/O PELTHOS THERAPEUTICS INC., 4020 STIRRUP CREEK DRIVE, SUITE 110, DURHAM
Signature: /s/ Ezra Friedberg
Signature date: 07 Jul 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PTHS transaction Derivative

Restricted Stock Units

Award

Transaction value
Shares: +19,108
Change %: +215%
Price
Shares after: 28,012
Date: 02 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 19,108
Exercise price: $13.50
Footnotes: F1, F3

PTHS transaction Derivative

Stock Option

Award

Transaction value
Shares: +58,230
Change %
Price
Shares after: 58,230
Date: 02 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 58,230
Exercise price: $13.50
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

On July 2, 2025, the Reporting Person was granted stock restricted stock units to purchase 19,108 shares of common stock at an exercise price of $13.50 per share, which shall vest on a quarterly basis over a period of three (3) years.

Footnote F2

On July 2, 2025, the Reporting Person was granted stock options to purchase 58,230 shares of common stock at an exercise price of $13.50 per share, which shall vest on a quarterly basis over a period of three (3) years.

Footnote F3

The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.